GSK
Pays vs peer median
×1.03
+3% premium
Sample
15
high confidence
Last refreshed
2026-04-13
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×1.06 | 10 |
By stage at signing
| Phase | Premium | Deals |
|---|---|---|
| phase 2 | ×1.17 | 5 |
| preclinical | ×0.72 | 5 |
| approved | ×1.14 | 3 |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2025 | TROP2-201 | Immunogen | Gastric | preclinical | $43M | $367M |
| 2025 | CD40-tinib | Monte Rosa Therapeutics | DLBCL | phase_3 | — | $613M |
| 2025 | FRα-101 | Revolution Medicines | HCC | phase_3 | $608M | $3.3B |
| 2025 | PARP-201 | Syros Pharmaceuticals | Cholangiocarcinoma | preclinical | $80M | $1.2B |
| 2025 | gastrointestinal stromal tumor | IDRx | gastrointestinal stromal tumor | phase_2 | $1.0B | $1.0B |
| 2025 | multi-indication | Hengrui Pharma | multi-indication | phase_1 | $500M | $12.5B |
| 2025 | Anti-WEE1-mab | Denali Therapeutics | Breast (HR+) | discovery | $44M | $576M |
| 2025 | Mesothelin-mab | Elevation Oncology | Breast (HER2+) | approved | — | $226M |
| 2025 | CD19-tinib | Vor Biopharma | Cholangiocarcinoma | discovery | $19M | $323M |
| 2025 | Efimosfermin alfa (MASH FGF21) | Boston Pharmaceuticals | MASH, MASH cirrhosis, ALD | phase_2 | $1.2B | $2.0B |
| 2025 | ATR-mab | Syndax Pharmaceuticals | NSCLC | phase_2 | $539M | $5.9B |
| 2025 | HER2 | BioNTech | GBM | phase_3 | $218M | $1.1B |
| 2024 | SIRPα-mab | Deciphera Pharmaceuticals | SCLC | discovery | $40M | $568M |
| 2024 | CSF1R-001 | Umoja Biopharma | Multiple Myeloma | approved | $1.7B | $5.5B |
| 2024 | PD-L1-mab | Sana Biotechnology | Pancreatic | discovery | $8M | $118M |
How this is computed
For each GSK deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 15 disclosed deal premiums vs. peer medians. Raw premium 1.035, clamped to [0.7, 1.5].